Clinical Trial 23572

• Overview

  Study Title:

  Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

  Objective:

  Primary Objective: * Evaluate the efficacy of elacestrant relative to standard endocrine therapy in terms of IBCFS in participants with node-positive, estrogen receptor-positive, HER2-negative early breast cancer with high risk of recurrence. Key Secondary Objectives: * Evaluate the efficacy of elacestrant relative to standard of care (SoC) in terms of distant relapse-free survival (DRFS). * Evaluate the efficacy of elacestrant relative to SoC in terms of overall survival (OS). Secondary Objectives: * Evaluate the efficacy of elacestrant relative to SoC in terms of invasive disease-free survival (IDFS). * Characterize the safety of elacestrant in the trial patient population. * Evaluate the effect of elacestrant relative to SoC on patient-reported outcomes (PROs). * Characterize elacestrant steady-state pharmacokinetics (PK) and exposure-response relationships (efficacy and safety)

• Treatments

  Therapies:

  Hormonal Therapy

  Medications:

  Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Elacestrant (); Exemestane (); Femara (Letrozole); Letrozole (); Tamoxifen ()

• Inclusion Criteria

  Key Inclusion Criteria:
  • Histopathologically or cytologically confirmed ER+ (≥ 10 % by immunohistochemistry [IHC]), HER2- [IHC = 0, 1+, or 2+ and in situ hybridization [ISH] negative [not amplified]). ISH-negative without IHC testing will also be eligible on tumor biopsy or final surgical pathology specimen early stage resected invasive breast cancer without evidence of recurrence or distant metastases, per local laboratory, according to the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) guidelines.
  • Participants who are currently taking endocrine therapy (AIs or tamoxifen) and have received at least 24 months but not more than 60 months of endocrine therapy at the time of randomization (C1D1), with or without a CDK4/6i, and with or without an LHRH agonist. Participants who received prior CDK4/6i or a poly ADP-ribose polymerase (PARP) inhibitor must have already completed or discontinued these treatments as per the washout period prior to randomization.
  • Additional criteria apply.

• Exclusion Criteria

  Key Exclusion Criteria:
  • Participants with inflammatory breast cancer.
  • History of any prior (ipsilateral and / or contralateral) invasive breast cancer.
  • Participants who have had more than 6-months continuous interruption of prior SoC adjuvant endocrine therapy or who are off current adjuvant endocrine therapy more than 6 months prior to randomization.
  • Other exclusions apply

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.